Results 71 to 80 of about 48,812 (228)

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem, Melissa M. de Meza, Cato D. M. Boreel, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Bart Rikhof, Lieke H. J. Simkens, Marion A. Stevense‐den Boer, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Alfonsus J. M. van den Eertwegh, Michel W. J. M. Wouters   +20 more
wiley   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Case Reports in Oncology, 2017
Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab ...
Lieke van Montfort, Caroline M. Loos, Monique Anten, Rob L.H. Jansen   +3 more
doaj   +1 more source

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

The Journal of Dermatology, EarlyView.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du, Anika Jallorina, Toru Yoshino, Lingyu Bao, Han Bao, Victor Chang, Henry K. Wong, Derek V. Chan, Stephen K. Richardson, Mary F. Lee‐Wong   +9 more
wiley   +1 more source

Use of ipilimumab in the treatment of melanoma

, 2013
Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been ...
Acharya UH, Jeter JM
core  

Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients

Allergy, EarlyView.
Skin tape strip lipidomic analysis revealed preexisting skin barrier lipid abnormalities at day 0 that were further exacerbated after 6 weeks of CPI treatment. Significant changes in skin (but not plasma) proinflammatory cytokines were identified in future ircAE patients after 6 weeks of CPI immunotherapy.
Taras Lyubchenko, Evgeny Berdyshev, Ryan M. Weight, Olivia Xiao, Neil J. Shah, Alina Markova, Mario E. Lacouture, Jeffrey A. Kern, Elena Goleva, Donald Y. M. Leung   +9 more
wiley   +1 more source

Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)

[Accompanying Article] Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)[Purpose] There are limited treatment options ...
Dalle, Stephane, Leccia, Marie-Therese, Chunduru, Srinivas, Arenberger, Petr, Krajsova, Ivana, Walker, John W. T., Kapiteijn, Ellen, Guidoboni, Massimo, Butler, Marcus O., In, Gino K., Negrier, Sylvie, Maio, Michele, Loquai, Carmen, Lebbe, Celeste, Robert, Caroline, Abdel-Wahab, Reham, Rahimian, Shahram, Mortier, Laurent, Grob, Jean-Jacques, Guida, Michele, Diab, Adi, Ascierto, Paolo A., Haferkamp, Sebastian, Cruz-Merino, Luis de la, Atkinson, Victoria   +24 more
core   +1 more source

Ipilimumab: A Novel Treatment for Metastatic Melanoma

, 2011
Objective: To review the mechanism of action, pharmacokinetics, efficacy, safety, drug interactions, dosing, and economic considerations of ipilimumab.
Morgan E Culver, Erin E Mancl, Mandy L Gatesman, Denise K Lowe   +3 more
core   +1 more source

Improved survival with ipilimumab in patients with metastatic melanoma [PDF]

, 2010
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab - which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response ...
Sosman, Jeffrey A., Ottensmeier, C.H., Lebbe, C., Hodi, F. Stephen, Haanen, JB, Peschel, Christian, Jeffrey S. Weber, Nichol, Geoffrey M., O'Day, Steven J., van den Eertwegh, Alfons J.M., Hogg, D., Jessica C. Hassel, Lorigan, P., Walter J. Urba, Vaubel, J.M., Lutzky, J., Caroline Robert, Axel Hoos, Michael J. Yellin, McDermott, D.F., David Hogg, Robert W. Weber, Peschel, C., Wolchok, J.D., John B. Haanen, Robert, Caroline, Steven J. O'Day, Quirt, Ian, Weber, R.W., David F. McDermott, Lorigan, Paul; id_orcid, Dirk Schadendorf, Joseph I. Clark, Christian H. Ottensmeier, Hassel, Jessica C., Haanen, John B., Linette, G.P., McDermott, David F., Wolchok, Jedd D., Clark, J.I., Rene Gonzalez, Celeste Lebbé, Van Den Eertwegh, Alfons J M, Akerley, W., Clark, Joseph I., Gonzalez, R., Jedd D. Wolchok, Hoos, A., Ian Quirt, F. Stephen Hodi, Jeffrey A. Sosman, Paul Lorigan, Linette, Gerald P., et al,, Christian Peschel, Jose Lutzky, Vaubel, Julia M., O'Day, S.J., Nichol, G.M., Weber, J.S., Schadendorf, D., Geoffrey M. Nichol, Ottensmeier, Christian H., Hassel, J.C., Wallace Akerley, Gonzalez, Rene, van den Eertwegh, A.J.M., Weber, Robert W., Lutzky, Jose, Robert, C., Hogg, David, Schadendorf, Dirk, Weber, Jeffrey S., Quirt, I., Tian, Jason, Tian, J., Jason Tian, Yellin, Michael J., Hoos, Axel, Urba, Walter J., Akerley, Wallace, Linette, Gerald P, Lebbé, Celeste, Hodi, F.S., Urba, WJ, Julia M. Vaubel, Sosman, J.A., Yellin, M.J., Gerald P. Linette, Alfons J.M. van den Eertwegh, Lorigan, Paul, Clark, Joseph I, Hodi, FS;O'Day, SJ;McDermott, DF;Weber, RW;Sosman, JA;Haanen, JB;Gonzalez, R;Robert, C;Schadendorf, D;Hassel, JC;Akerley, W;van den Eertwegh, AJ;Lutzky, J;Lorigan, P;Vaubel, JM;Linette, GP;Hogg, D;Ottensmeier, CH;Lebbe, C;Peschel, C;Quirt, I;Clark, JI;Wolchok, JD;Weber, JS;Tian, J;Yellin, MJ;Nichol, GM;Hoos, A;Urba, WJ, Weber, Robert W, McDermott, David F, Lorigan, Paul C, Haanen, John B, Yellin, Michael J, O'Day, Steven, Ottensmeier, Christian H, Weber, Jeffrey S, Hassel, Jessica C, Urba, Walter J, Vaubel, Julia M, Sosman, Jeffrey A, Nichol, Geoffrey M, Hodi, F Stephen, Wolchok, Jedd D   +107 more
core   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC).
Bin Wu, Qiang Zhang, Jie Sun
doaj   +1 more source